Skip to content

Category Archives: Polymer coated onto the outer abluminal side of the ste

Biosensors International Group > Receives CE Mark Approval for its BioMatrix Drug-Eluting Coronary Stent System > BioMatrix and NOBORI drug-eluting stents > Stents incorporate a biodegradable polymer coating together with an immunosuppressive drug

Saturday, January 19, 2008

Will BioMatrix provide a valuable alternative to the drug-eluting stents currently available to interventional cardiologists? Is the three-year follow-up data released at the Transcatheter Cardiovascular Therapeutics Conference showing BioMatrix’s superior results in terms of safety and clinical effectiveness? Will the increasing complexity of worldwide regulatory requirements make it more difficult in the future to introduce […]

Filed in PLA polymer fully degrades into water and carbon dioxid, Leaving in place a biocompatible stent surface, Drug has a higher lipophilic and hydrophobic profile, Immunosuppressive and anti-inflammatory properties, NOBORI drug-eluting stent system, Polymer coated onto the outer abluminal side of the ste, Drug to be released to targeted tissue, Transcatheter Cardiovascular Therapeutics Conference, Siegburg Heart Center, Eberhard Grube, Three separate drug-eluting stent programs, Terumo Corporation, Biolimus A9 biodegradable polymer and advanced stent de, Biosensors International Group, Medical Device Company, Efficacy, Medical Universities Research Institutes Med Societies, BioMatrix, Axxion, BioMatrix clinical trial program, Drug eluting stents, Licensed aspects of its drug-eluting stent technology t, BioMatrixFreedom polymer-free drug-eluting stent, Endoluminal Endolumenal Hollow Vessel | Comments (0)